drugset / Trial / NCT00775372

Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions

NCT00775372

Completed 40 enrolled Ranbaxy Laboratories Limited
RandomizedCrossoverOpen-label

Summary

To compare the single-dose oral bioavailability of clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories with Biaxin 250 mg/5 mL granules for oral suspension in healthy, adult, human, male subjects under fed conditions

Timeline

Start
2005-09
Primary completion
2005-10
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 250 mg Oral

Indications

No indication recorded.